Back to News
Market Impact: 0.18
Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Rodman & Renshaw initiated coverage of Quince Therapeutics (NASDAQGS: QNCX) with a Buy recommendation on September 24, 2026. QNCX closed at $30.15 on September 23, unchanged from its pre-action close, indicating no reported immediate market reaction in the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
QNCX0.45
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- AMD shares are primed for a comeback, says Oppenheimer
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?